Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:** \n2,3-dimethoxy-12H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinolin-6-ium is an experimental small molecule belonging to the isoquinoline and derivatives class of organic compounds. It is a polycyclic aromatic compound with the molecular formula C19H16NO4 and a monoisotopic mass of approximately 322.11 g/mol. The compound has been studied as part of a broader class of indenoisoquinolines for their potential anticancer properties due to their ability to inhibit DNA topoisomerase I—a key enzyme involved in DNA replication and transcription.\n\nIndenoisoquinolines (including closely related analogs) have demonstrated strong cytotoxicity in cancer cell lines by stabilizing the covalent complex between topoisomerase I and DNA (the "cleavable complex"), thereby preventing religation of single-strand breaks during DNA replication and leading to cell death in rapidly dividing cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2,3-dimethoxy-12H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinolin-6-ium.